BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: First quarter 2026 revenue of $21.1 million54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026$524 million in cash & investments as of March 31, 2026, excluding $25 million earnout received after quarter en ...